 Risha Gidwani
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare | 9 | 2022 | 808 | 3.210 |
Why?
| | Deductibles and Coinsurance | 3 | 2026 | 12 | 2.020 |
Why?
| | Insurance, Health | 4 | 2026 | 299 | 1.870 |
Why?
| | Cost Sharing | 2 | 2026 | 19 | 1.820 |
Why?
| | Neoplasms | 10 | 2023 | 2761 | 1.440 |
Why?
| | Quality of Health Care | 4 | 2020 | 649 | 1.260 |
Why?
| | Hospice Care | 4 | 2019 | 205 | 1.140 |
Why?
| | Patient Protection and Affordable Care Act | 2 | 2026 | 99 | 1.080 |
Why?
| | Terminal Care | 4 | 2020 | 253 | 1.050 |
Why?
| | Lumbar Vertebrae | 4 | 2016 | 252 | 1.030 |
Why?
| | Oncologists | 2 | 2018 | 44 | 1.010 |
Why?
| | United States | 26 | 2026 | 15447 | 1.000 |
Why?
| | Veterans | 8 | 2020 | 1531 | 0.970 |
Why?
| | Health Insurance Exchanges | 1 | 2026 | 2 | 0.960 |
Why?
| | Ambulatory Care | 2 | 2020 | 598 | 0.930 |
Why?
| | United States Department of Veterans Affairs | 7 | 2020 | 723 | 0.930 |
Why?
| | Health Status | 2 | 2025 | 822 | 0.930 |
Why?
| | Hepatitis C, Chronic | 2 | 2019 | 149 | 0.920 |
Why?
| | Hospitals, Veterans | 5 | 2020 | 255 | 0.890 |
Why?
| | Telemedicine | 2 | 2024 | 911 | 0.850 |
Why?
| | Insurance, Health, Reimbursement | 2 | 2015 | 100 | 0.850 |
Why?
| | Health Care Reform | 2 | 2015 | 109 | 0.840 |
Why?
| | Financial Management | 1 | 2023 | 15 | 0.820 |
Why?
| | Venous Thrombosis | 2 | 2015 | 194 | 0.780 |
Why?
| | Risk Adjustment | 2 | 2020 | 83 | 0.770 |
Why?
| | Pulmonary Embolism | 2 | 2015 | 239 | 0.750 |
Why?
| | Patient Acceptance of Health Care | 3 | 2024 | 879 | 0.740 |
Why?
| | Medical Overuse | 3 | 2016 | 29 | 0.720 |
Why?
| | Chronic Disease | 4 | 2025 | 1815 | 0.700 |
Why?
| | Veterans Health | 2 | 2020 | 186 | 0.680 |
Why?
| | Guideline Adherence | 1 | 2025 | 565 | 0.660 |
Why?
| | Hospitalization | 4 | 2020 | 2293 | 0.640 |
Why?
| | Eligibility Determination | 1 | 2020 | 70 | 0.630 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 220 | 0.630 |
Why?
| | Aged | 21 | 2025 | 25117 | 0.620 |
Why?
| | Fee-for-Service Plans | 1 | 2019 | 89 | 0.590 |
Why?
| | Breast Neoplasms | 2 | 2021 | 2272 | 0.590 |
Why?
| | Comorbidity | 2 | 2021 | 1678 | 0.580 |
Why?
| | Public Health | 1 | 2023 | 561 | 0.560 |
Why?
| | Patient Admission | 1 | 2020 | 203 | 0.560 |
Why?
| | Humans | 43 | 2026 | 142526 | 0.540 |
Why?
| | Medicare Part C | 1 | 2018 | 31 | 0.540 |
Why?
| | Low Back Pain | 2 | 2016 | 109 | 0.530 |
Why?
| | Cost-Benefit Analysis | 5 | 2025 | 618 | 0.530 |
Why?
| | Cancer Survivors | 1 | 2022 | 289 | 0.530 |
Why?
| | Female | 30 | 2026 | 76624 | 0.530 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 285 | 0.520 |
Why?
| | Length of Stay | 2 | 2019 | 1273 | 0.500 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1037 | 0.500 |
Why?
| | Middle Aged | 20 | 2026 | 35049 | 0.500 |
Why?
| | Patient Care Management | 1 | 2016 | 55 | 0.500 |
Why?
| | Vaccines | 1 | 2022 | 409 | 0.490 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 138 | 0.490 |
Why?
| | Menorrhagia | 2 | 2013 | 22 | 0.490 |
Why?
| | Intrauterine Devices, Medicated | 2 | 2013 | 27 | 0.480 |
Why?
| | Physicians, Family | 1 | 2017 | 192 | 0.470 |
Why?
| | Retrospective Studies | 13 | 2023 | 16626 | 0.470 |
Why?
| | Decision Making | 2 | 2020 | 957 | 0.470 |
Why?
| | Documentation | 1 | 2017 | 194 | 0.460 |
Why?
| | Palliative Care | 4 | 2017 | 841 | 0.460 |
Why?
| | Job Satisfaction | 1 | 2017 | 229 | 0.450 |
Why?
| | Male | 25 | 2026 | 70910 | 0.450 |
Why?
| | Consumer Health Information | 1 | 2015 | 49 | 0.440 |
Why?
| | Proline | 1 | 2014 | 80 | 0.420 |
Why?
| | Intensive Care Units | 2 | 2019 | 874 | 0.420 |
Why?
| | Endometrial Ablation Techniques | 1 | 2013 | 2 | 0.410 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2014 | 139 | 0.400 |
Why?
| | Family Practice | 1 | 2017 | 441 | 0.400 |
Why?
| | Menstruation | 1 | 2013 | 43 | 0.400 |
Why?
| | Patient Satisfaction | 1 | 2017 | 697 | 0.390 |
Why?
| | Antiviral Agents | 2 | 2019 | 758 | 0.390 |
Why?
| | Oligopeptides | 1 | 2014 | 266 | 0.380 |
Why?
| | Emergency Service, Hospital | 3 | 2015 | 2251 | 0.380 |
Why?
| | Insurance Coverage | 2 | 2026 | 240 | 0.370 |
Why?
| | Attitude of Health Personnel | 3 | 2018 | 1194 | 0.370 |
Why?
| | AIDS Serodiagnosis | 1 | 2011 | 23 | 0.340 |
Why?
| | Spinal Fusion | 1 | 2014 | 260 | 0.340 |
Why?
| | Azacitidine | 1 | 2011 | 149 | 0.330 |
Why?
| | Internet | 1 | 2015 | 694 | 0.320 |
Why?
| | Myelodysplastic Syndromes | 1 | 2011 | 143 | 0.310 |
Why?
| | Adult | 12 | 2026 | 39715 | 0.280 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 837 | 0.270 |
Why?
| | Hospices | 3 | 2018 | 89 | 0.270 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1404 | 0.270 |
Why?
| | Disease Progression | 1 | 2015 | 2831 | 0.260 |
Why?
| | Administrative Claims, Healthcare | 2 | 2018 | 26 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3776 | 0.250 |
Why?
| | California | 3 | 2025 | 465 | 0.250 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1353 | 0.250 |
Why?
| | Quality-Adjusted Life Years | 2 | 2025 | 112 | 0.240 |
Why?
| | Primary Health Care | 1 | 2016 | 1768 | 0.240 |
Why?
| | Hepacivirus | 2 | 2019 | 242 | 0.230 |
Why?
| | Taxes | 1 | 2025 | 15 | 0.230 |
Why?
| | Carbonated Beverages | 1 | 2025 | 16 | 0.230 |
Why?
| | Mass Screening | 2 | 2011 | 1325 | 0.230 |
Why?
| | Logistic Models | 2 | 2023 | 2102 | 0.220 |
Why?
| | Hospitals, Private | 1 | 2023 | 12 | 0.210 |
Why?
| | Pandemics | 2 | 2023 | 1661 | 0.210 |
Why?
| | Interviews as Topic | 2 | 2018 | 857 | 0.200 |
Why?
| | Levonorgestrel | 2 | 2013 | 36 | 0.200 |
Why?
| | Cross-Sectional Studies | 2 | 2026 | 5700 | 0.190 |
Why?
| | Aged, 80 and over | 6 | 2024 | 8020 | 0.190 |
Why?
| | Young Adult | 6 | 2025 | 13878 | 0.180 |
Why?
| | Medically Uninsured | 1 | 2022 | 135 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2024 | 306 | 0.170 |
Why?
| | Privatization | 1 | 2020 | 7 | 0.170 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2980 | 0.160 |
Why?
| | Qualitative Research | 2 | 2018 | 1546 | 0.160 |
Why?
| | Probability | 1 | 2020 | 307 | 0.160 |
Why?
| | Financing, Personal | 1 | 2019 | 28 | 0.150 |
Why?
| | Publishing | 1 | 2020 | 109 | 0.150 |
Why?
| | HIV Infections | 2 | 2011 | 3003 | 0.150 |
Why?
| | Medicaid | 1 | 2023 | 457 | 0.140 |
Why?
| | Databases, Factual | 2 | 2014 | 1458 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 690 | 0.140 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 1284 | 0.140 |
Why?
| | Needs Assessment | 1 | 2020 | 391 | 0.140 |
Why?
| | Health Expenditures | 1 | 2019 | 194 | 0.140 |
Why?
| | Blood Pressure | 1 | 2024 | 1745 | 0.130 |
Why?
| | Adolescent | 4 | 2025 | 22326 | 0.130 |
Why?
| | Cost of Illness | 1 | 2019 | 316 | 0.130 |
Why?
| | Bereavement | 1 | 2017 | 58 | 0.130 |
Why?
| | Alcohol Deterrents | 1 | 2016 | 19 | 0.120 |
Why?
| | Utilization Review | 1 | 2016 | 41 | 0.120 |
Why?
| | Hypertension | 1 | 2024 | 1257 | 0.120 |
Why?
| | Drug Therapy | 1 | 2015 | 81 | 0.110 |
Why?
| | Alcohol-Related Disorders | 1 | 2016 | 127 | 0.110 |
Why?
| | Publications | 1 | 2015 | 48 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 346 | 0.110 |
Why?
| | Radiotherapy | 1 | 2015 | 206 | 0.110 |
Why?
| | Genotyping Techniques | 1 | 2014 | 72 | 0.110 |
Why?
| | Policy Making | 1 | 2014 | 81 | 0.110 |
Why?
| | Cell Phone | 1 | 2015 | 82 | 0.110 |
Why?
| | Medical Informatics | 1 | 2015 | 99 | 0.110 |
Why?
| | Ribavirin | 1 | 2014 | 82 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2016 | 283 | 0.110 |
Why?
| | Confidence Intervals | 1 | 2014 | 330 | 0.100 |
Why?
| | Cohort Studies | 2 | 2023 | 5858 | 0.100 |
Why?
| | Drug Utilization | 1 | 2014 | 166 | 0.100 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 78 | 0.100 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 616 | 0.100 |
Why?
| | Danazol | 1 | 2013 | 1 | 0.100 |
Why?
| | Interferon-alpha | 1 | 2014 | 196 | 0.100 |
Why?
| | Interferons | 1 | 2014 | 195 | 0.100 |
Why?
| | Odds Ratio | 1 | 2016 | 1057 | 0.100 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 584 | 0.100 |
Why?
| | Interleukins | 1 | 2014 | 252 | 0.100 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2022 | 1407 | 0.100 |
Why?
| | Progestins | 1 | 2013 | 84 | 0.100 |
Why?
| | Parents | 1 | 2022 | 1450 | 0.100 |
Why?
| | Family | 1 | 2017 | 682 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 2103 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2020 | 11298 | 0.090 |
Why?
| | Respiration, Artificial | 1 | 2017 | 694 | 0.090 |
Why?
| | Patient Compliance | 1 | 2016 | 613 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1255 | 0.090 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2014 | 189 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1053 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 3027 | 0.090 |
Why?
| | Reoperation | 1 | 2014 | 600 | 0.090 |
Why?
| | Bayes Theorem | 1 | 2013 | 424 | 0.090 |
Why?
| | Communication | 1 | 2016 | 949 | 0.080 |
Why?
| | Surveys and Questionnaires | 3 | 2023 | 5994 | 0.080 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2014 | 372 | 0.080 |
Why?
| | Community-Based Participatory Research | 1 | 2010 | 168 | 0.070 |
Why?
| | Quality of Life | 2 | 2018 | 3064 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1128 | 0.070 |
Why?
| | Electronic Health Records | 1 | 2016 | 1144 | 0.070 |
Why?
| | Incidence | 1 | 2014 | 2826 | 0.070 |
Why?
| | Health Care Costs | 1 | 2011 | 422 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1642 | 0.060 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2568 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2014 | 3604 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2167 | 0.060 |
Why?
| | Risk Assessment | 1 | 2014 | 3562 | 0.060 |
Why?
| | Health Surveys | 1 | 2025 | 511 | 0.050 |
Why?
| | Brazil | 1 | 2022 | 177 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2010 | 1042 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2014 | 2862 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 441 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2817 | 0.030 |
Why?
| | Disulfiram | 1 | 2016 | 15 | 0.030 |
Why?
| | Consumer Behavior | 1 | 2017 | 71 | 0.030 |
Why?
| | Taurine | 1 | 2016 | 40 | 0.030 |
Why?
| | Fructose | 1 | 2016 | 118 | 0.030 |
Why?
| | Naltrexone | 1 | 2016 | 111 | 0.030 |
Why?
| | Nursing Homes | 1 | 2017 | 174 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2015 | 161 | 0.030 |
Why?
| | Colonic Neoplasms | 1 | 2015 | 253 | 0.020 |
Why?
| | Pregnancy, Unplanned | 1 | 2013 | 46 | 0.020 |
Why?
| | Models, Economic | 1 | 2013 | 61 | 0.020 |
Why?
| | Hysterectomy | 1 | 2013 | 139 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1977 | 0.020 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 558 | 0.020 |
Why?
| | Risk Factors | 1 | 2024 | 10593 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2010 | 137 | 0.020 |
Why?
| | Liver Neoplasms | 1 | 2015 | 755 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2010 | 274 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 3362 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 1054 | 0.020 |
Why?
| | Program Evaluation | 1 | 2010 | 928 | 0.010 |
Why?
| | Pregnancy | 1 | 2013 | 7113 | 0.010 |
Why?
|
|
Gidwani's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|